The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients

Sarilumab Trial Data Shows It May Only Help Critical COVID-19 Patients

April 27, 2020 • By Saumya Joseph

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—On April 27, Regeneron Pharmaceuticals Inc. and Sanofi SA said on Monday that their arthritis drug sarilumab (Kevzara) may only help the sickest patients with COVID-19, dampening hopes that the therapy could potentially reach a larger pool of patients with the disease.

You Might Also Like
  • Sarilumab Investigated to Treat COVID-19
  • Tocilizumab Fails to Help COVID-19 Patients in Italian Study
  • U.K. Healthcare Workers Begin COVID-19 HCQ Trial

The drugmakers said they would test high doses of sarilumab only in critically ill COVID-19 patients based on guidance from an independent committee that reviewed early trial data, which showed the drug was not beneficial for severe patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There are currently no approved treatments to treat the new coronavirus and drugmakers are rushing to repurpose existing drugs as well as test experimental therapies in infected patients.

Early analysis of the study showed that sarilumab rapidly lowered levels of C-reactive protein, a key marker of inflammation. However, the companies found negative trends for most outcomes in severe patients, while there were positive trends for all outcomes in the critical” group.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients who required mechanical ventilation or high-flow oxygenation or required treatment in an intensive care unit were considered critical, while those who required oxygen supply without mechanical or high-flow oxygenation were considered severe.

The mixed results raise concerns that sarilumab’s benefit in critical COVID-19 patients could be a spurious conclusion and may not indicate any real benefit by the therapy, says RBC Capital Markets analyst Kennen MacKay.

Sarilumab belongs to a class of drugs called interleukin (IL) 6 inhibitors that could help regulate an overreaction to the virus by the body’s immune system, which may be triggering the respiratory distress seen in severe COVID-19 cases.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

However, a French study of Roche Holding AG’s IL-6 inhibitor tocilizumab (Actemra) found a significantly lower number of patients on the drug needed a ventilator or died, suggesting that the class of drugs may be beneficial, says Credit Suisse Analyst Evan Seigerman.

Regeneron has also identified hundreds of virus-neutralizing antibodies and is working to select the best two candidates for a cocktail therapy that may treat and even prevent the disease, with the expectation of starting human trials in June.

Regeneron’s shares, which have risen 51% so far this year, fell 4.6% to $540.41 in morning trading.

Reporting by Manas Mishra and Saumya Sibi Joseph in Bengaluru; Editing by Anil D’Silva and Ramakrishnan M

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, sarilumab, tocilizumab

You Might Also Like:
  • Sarilumab Investigated to Treat COVID-19
  • Tocilizumab Fails to Help COVID-19 Patients in Italian Study
  • U.K. Healthcare Workers Begin COVID-19 HCQ Trial
  • Arthritis Drug Anakinra Shows Promise in COVID-19

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)